These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 36671672)

  • 41. SARS-CoV-2 M
    Bharadwaj S; Azhar EI; Kamal MA; Bajrai LH; Dubey A; Jha K; Yadava U; Kang SG; Dwivedi VD
    J Biomol Struct Dyn; 2022 Apr; 40(6):2769-2784. PubMed ID: 33150855
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of potent compounds against SARs-CoV-2: An in-silico based drug searching against Mpro.
    Hassam M; Bashir MA; Shafi S; Zahra NU; Khan K; Jalal K; Siddiqui H; Uddin R
    Comput Biol Med; 2022 Dec; 151(Pt A):106284. PubMed ID: 36370580
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays.
    Gupta Y; Maciorowski D; Zak SE; Jones KA; Kathayat RS; Azizi SA; Mathur R; Pearce CM; Ilc DJ; Husein H; Herbert AS; Bharti A; Rathi B; Durvasula R; Becker DP; Dickinson BC; Dye JM; Kempaiah P
    Methods; 2021 Nov; 195():57-71. PubMed ID: 33453392
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovering potent inhibitors against the Mpro of the SARS-CoV-2. A medicinal chemistry approach.
    Mehmood A; Nawab S; Wang Y; Chandra Kaushik A; Wei DQ
    Comput Biol Med; 2022 Apr; 143():105235. PubMed ID: 35123137
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some
    Amin SA; Ghosh K; Gayen S; Jha T
    J Biomol Struct Dyn; 2021 Aug; 39(13):4764-4773. PubMed ID: 32568618
    [TBL] [Abstract][Full Text] [Related]  

  • 47.
    Kumar B; Parasuraman P; Murthy TPK; Murahari M; Chandramohan V
    J Biomol Struct Dyn; 2022 Oct; 40(17):7796-7814. PubMed ID: 33759690
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drug Repurposing to Identify Nilotinib as a Potential SARS-CoV-2 Main Protease Inhibitor: Insights from a Computational and
    Banerjee S; Yadav S; Banerjee S; Fakayode SO; Parvathareddy J; Reichard W; Surendranathan S; Mahmud F; Whatcott R; Thammathong J; Meibohm B; Miller DD; Jonsson CB; Dubey KD
    J Chem Inf Model; 2021 Nov; 61(11):5469-5483. PubMed ID: 34666487
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
    Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
    Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
    [TBL] [Abstract][Full Text] [Related]  

  • 51.
    Santiago-Silva KM; Camargo P; Felix da Silva Gomes G; Sotero AP; Orsato A; Perez CC; Nakazato G; da Silva Lima CH; Bispo M
    J Biomol Struct Dyn; 2023; 41(16):7686-7699. PubMed ID: 36124832
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Importance of glutamine 189 flexibility in SARS-CoV-2 main protease: Lesson learned from in silico virtual screening of ChEMBL database and molecular dynamics.
    Said MA; Albohy A; Abdelrahman MA; Ibrahim HS
    Eur J Pharm Sci; 2021 May; 160():105744. PubMed ID: 33540040
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Structure-Based Virtual Screening to Discover Potential Lead Molecules for the SARS-CoV-2 Main Protease.
    Gahlawat A; Kumar N; Kumar R; Sandhu H; Singh IP; Singh S; Sjöstedt A; Garg P
    J Chem Inf Model; 2020 Dec; 60(12):5781-5793. PubMed ID: 32687345
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
    Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A
    PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.
    Ancy I; Sivanandam M; Kumaradhas P
    J Biomol Struct Dyn; 2021 Sep; 39(15):5368-5375. PubMed ID: 32627689
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors - an
    Ghosh R; Chakraborty A; Biswas A; Chowdhuri S
    J Biomol Struct Dyn; 2021 Aug; 39(12):4362-4374. PubMed ID: 32568613
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In silico analysis and identification of promising hits against 2019 novel coronavirus 3C-like main protease enzyme.
    Chatterjee S; Maity A; Chowdhury S; Islam MA; Muttinini RK; Sen D
    J Biomol Struct Dyn; 2021 Sep; 39(14):5290-5303. PubMed ID: 32608329
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Screening of potent phytochemical inhibitors against SARS-CoV-2 protease and its two Asian mutants.
    Muhammad I; Rahman N; Gul-E-Nayab ; Niaz S; Basharat Z; Rastrelli L; Jayanthi S; Efferth T; Khan H
    Comput Biol Med; 2021 Jun; 133():104362. PubMed ID: 33894500
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking.
    Vázquez-Mendoza LH; Mendoza-Figueroa HL; García-Vázquez JB; Correa-Basurto J; García-Machorro J
    Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409348
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Screening of potential inhibitors targeting the main protease structure of SARS-CoV-2
    Yang X; Xing X; Liu Y; Zheng Y
    Front Pharmacol; 2022; 13():962863. PubMed ID: 36278156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.